Investor Presentation May 2, 2017

Transcription

1 CSE: TBP OTC: GRPOF Investor Presentation May 2, 2017

2 Forward Looking Statements This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the expectations and projections of Tetra Bio-Pharma Inc. The information contained in this presentation has not been approved or disapproved by any Securities Commission in Canada, The Securities and Exchange Commission in the US or other regulatory body. Except for statements of historical fact relating to the Company, certain information contained herein constitutes "forward-looking statements". Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors include the inherent risks involved in the development of botanical based pharmaceuticals or medical devices regulated by Health Canada, the FDA or other international regulatory agencies, product obsolescence, the uncertainties involved in patent defense and complexities and timelines associated with product approvals in multiple jurisdictions. The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader is cautioned not to place undue reliance on forward-looking statements. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or from omissions from the information in this presentation. 1

3 Company Snapshot Tetra Bio-Pharma is a bio-pharmaceutical company focused on cannabis Tetra implements a vertically integrated approach to the development production and distribution of plant based pharmaceuticals and Bio health products and supplements with a focus on cannabinoid research and product development Tetra Founded: 2015 CSE (TBP) CAD$0.69 OTCQB (GRPOF) US$0.51 Market Capitalization CAD$79M Shares Issued 115M Shares Fully Diluted 131M Insider Ownership 9.4% Cash/Equivalent (As of April 28, 2017) CAD$2.8M Cash Burn Rate/Month CAD$100K Employees 8 2

4 Innovations in Pharmaceutical Cannabis & Nutraceuticals Pharmaceutical development of Cannabis-based drug products Commercialization of Cannabisbased products for the cosmetic and supplement markets License application in system. Land kept for an interested partner 3

5 REPORT: The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020 Viridian Capital Advisors Wednesday, 02 December :43 (EST) 4

6 THE PHARMACEUTICAL APPROACH TO CANNABIS RESEARCH AND MEDICAL INNOVATION A Physician s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine A legal and ethical requirement Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer. According to Canadian and USA drug regulatory agencies, the is no evidence to support the safety and efficacy of marijuana for use in the treatment of pain or any other indication. TBP product development plan would provide the data necessary for drug regulatory agencies to grant marketing approval and physicians to prescribe or recommend our products. As cannabis becomes legalised across the globe the medical and scientific community would still require pharmaceutical consumer drug products developed with proper research, data and protocol. Insurance companies will only be able to cover the cost of products with Drug Identification Numbers. TBP takes the natural aspects of medical cannabis and applies the science of pharma to develop products that patients want, doctors want to prescribe and insurance companies will cover. 5

7 Tetra s Product Pipeline Tetra invests significant time and capital into a continuous and sustainable pipe line of products based on patient needs and driven by scientific R&D 6

8 Prescription Drugs PPP001: Bringing smoked marijuana to patients PPP002: Adjunct therapy for Breakthrough Cancer Pain PPP003: Monotherapy and Combination product oral administration Chronic pain, PTSD and other neurologic and psychiatric conditions PPTGR: R&D* Topical prescription drug for pain management To generate pipeline (create IP and disease-specific treatments) 7

9 Partnership #2: Bringing Cannabis-based Products to Retail Markets Develop and commercialize Cannabis-derived products for the consumer market NSERC funded Partnership with McGill University Target the USA and Canadian retail markets: Generate revenues from product sales in the Food, dietary supplement and cosmetic markets Launch THC and CBD-free extracts of Cannabis in 2017 Readiness to commercialize THC and CBD containing products in Canada when legalization is effective 8

10 Partnership #3 (PPP002): Co-Development Sustained Release of THC Co-Development with acquisition of technology if successful Phase II in patients Advantage over approved synthetic THC: Significant reduction of side effects in patients and stability at room temperature Phase I completed: Demonstrated that safety will be significantly superior 9

11 Partnership #4: Investment & Acquisition of R&D Stage Biotech Significantly increase potential to develop pipeline with strong IP AgroTek Health will launch a product approved by NNHPD that induces the CB1 receptor to relieve pain Replace the PPTGR technology (Topical pain relief) with this technology (THC and CBD containing topical drug). Pursue original development plan. IP protection for technology. Discovery stage R&D that will lead to new patented THC and CBD based therapies 10

12 GOAL OF PARTNERSHIP #5 (PPP003) Co-Development and commercialization of botanical combination (herb-cannabis) products: A partnership defined by a contractual agreement A Joint Venture (JV) owned by 3 rd Partnership and TBP PPP003 is the combination of extracts of hypnotic herb and Cannabis oil (extract or further refining of oil) Two track development: Cannabis oil as a monotherapy for anxiety and insomnia Combination product for same indications Therapeutic targets: Neurological, mental, psychiatric conditions (e.g., anxiety, reduced intake of antipsychotics, PTSD, insomnia) Psychiatrist already proactive using cannabis to lower doses of antipsychotic drugs or sleep and anxiety drugs (SSRI) 11

13 Partners Algorithme Pharma is conducting stage 1 clinical trials of PP001 in collaboration with Phyto Pain Pharma McGill University is collaborating with AgroTek and Grow Pros on an NSERC funded research study to develop consumer products containing cannabinoids The National Sciences and Engineering Research Council of Canada connects industry with world-firsts in knowledge and the people behind them, fueling R&D and leading to firsts in the marketplace. They have granted TBP subsidiary Grow Pros Cannabis with research funding related to the development of Consumer products in collaboration with the university of McGill Aphria is a publicaly traded producer of Medicinal Cannabis under license from the Canadian Federal Government Aphria has partnered with Tetra for the production of Cannabis for use in PPP001 12

14 Cannabis / Medicinal Plant cultivation and sourcing Originally applied for ACMPR license in November of 2014, Currently in stage 3/5 Owns a lease option on 190 acres of agricultural land 45 min north of Ottawa Signed a co-op agreement with Delta 9 Bio tech to collaborate on licensing of the facility Currently examining alternative licensing options for Pharma Development and sourcing legal supply for use in Pharma and NHP products 13

15 Competitive Landscape GW Pharma $GWPH Market Capitalization: $3.0B USD GW Pharma has 2 products in its pipe line in stage 1 and stage 3 for epilepsy and MS Cannabis Science Inc. $CBIS Market Capitalization $171M USD Conducts qualitative research on medicinal cannabis in a non pharmaceutical manor. They have no products in Clinical Testing INSYS Therapeutics inc- $INSY Market Capitalization $811M USD Is a traditional Pharma company that was awarded organ drug status for CBD for treatment of GBM. They do not have any current clinical trials Zynerba Pharmaceuticals $ZYNE- Market Capitalization $278M USD Developing a synthetic THC transdermal patch as well as a synthetic CBD gel Cara Therapeutics Inc. $CARA Market Capitalization $505M USD R&D on Cannabinoid preceptors. Utilizing synthetic compounds 14

16 Capital Structure (as of April 30, 2017) Current Market Valuation ~79M Value Total Common Shares M Warrants exp 09/28/ M Compensation Warrants M OPTIONS exp 11/5/ M Average Price of Warrants: $0.20 Average Price of Options: $

17 Financing Jan 15 - Oct16 Raised ~$1.4M through private placements and executed warrants at October 2016 Secured 2M equity line of Credit from NYC private equity firm Alumina Partners November 2016 Closed a $914,000 financing round at.15 with a full 12 month warrant at.20 December 2016 $1M investment from with a.26 warrant forced exercise at.45 Closed a $479,100 financing round at.20 with a full 12 month warrant at.26 16

18 Leadership Executive Team Andre Rancourt Chief Executive Officer Guy Chamberland, PHD Chief Scientific officer Sabino Di Paola Chief Financial officer Ryan Brown VP, Business Development Edward Miller VP, IR & Corporate Communications Denis Courchesne VP, Sales Randy Ringuette, PHD Medical Researcher Charles Campbell, PHD Medical Researcher Board of Directors Andre Audet Chairman/Director Andre Rancourt Director Benoit Chotard Director Robert Brouillette Director 17

19 Contact Edward Miller VP, IR & Corporate Communications 18